Cordis said that it is the exclusive distributor of Presillion Plus, which is designed and manufactured by Medinol, Israel. Presillion Plus is a trademark of Cordis.

The Presillion Plus changes include a new hypotube for improved pushability in crossing calcified lesions and a redesigned semi-compliant balloon for precise stent deployment and decreased deflation time. It is available in lengths from 8 to 33mm including a new 28mm addition and in diameters from 2.5 to 4.0mm.

The Pionir study, designed to measure the safety and effectiveness of Presillion and Presillion Plus, completed enrollment at 16 sites in Europe and Israel. The study, conducted by Medinol, includes 278 patients and will evaluate clinical performance through one year.

Staffan Ternstrom, president of Cordis Europe, Middle-East, Africa, said: “Our vision at Cordis is to transform cardiovascular care, a field in which incredible progress has been made over the last decade, but one in which much more remains to be done. The new Presillion Plus further complements our portfolio with its technological advances. We will continue to deliver new solutions that save lives and improve the quality of life for people around the world.”

Campbell Rogers, global head of R&D at Cordis, said: “The new upgraded delivery system increases the speed of procedures with atraumatic delivery, increased pushability, and smoother withdrawal. We are very satisfied with the speed in which we were able to incorporate feedback from cardiologists into the new design.”